Free Trial
→ Your book attached (From Profits Run) (Ad)tc pixel
OTCMKTS:EDTXF

Spectral Diagnostics 5/13/2024 Earnings Report

Spectral Diagnostics logo
$1.03 +0.01 (+0.78%)
As of 03:22 PM Eastern
ProfileEarnings History

Spectral Diagnostics EPS Results

Actual EPS
-$0.01
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Spectral Diagnostics Revenue Results

Actual Revenue
$0.50 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Spectral Diagnostics Announcement Details

Quarter
Date
5/13/2024
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Spectral Diagnostics' next earnings date is estimated for Friday, May 8, 2026, based on past reporting schedules.

Conference Call Resources

Spectral Diagnostics Earnings Headlines

Spectral Medical Announces First Quarter 2026 Financial Results and Provides Corporate Update
May 8 at 7:30 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/08/3291013/0/en/spectral-medical-announces-first-quarter-2026-financial-results-and-provides-corporate-update.html
Spectral Diagnostics (EDTXF) Expected to Announce Earnings on Friday
May 1, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30750659
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners guide...please take a few seconds and download it right now before your download link expires. That way, no matter what it costs in the future, you'll have a free copy on your computer.tc pixel
May 8 at 1:00 AM  |  Profits Run (Ad)
Spectral Medical Announces Fourth Quarter and Fiscal 2025 Results and Provides Corporate Update
March 26, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/03/26/3262891/0/en/spectral-medical-announces-fourth-quarter-and-fiscal-2025-results-and-provides-corporate-update.html
Spectral Medical and Vantive Announce Publication of Complete Results from Spectral's Tigris Trial in the Lancet Respiratory Medicine
March 24, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/03/24/3261056/0/en/spectral-medical-and-vantive-announce-publication-of-complete-results-from-spectral-s-tigris-trial-in-the-lancet-respiratory-medicine.html
Spectral Medical Provides Update on PMA Submission Timing for PMX-20R
February 26, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/02/26/3245465/0/en/spectral-medical-provides-update-on-pma-submission-timing-for-pmx-20r.html
See More Spectral Diagnostics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Spectral Diagnostics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Spectral Diagnostics and other key companies, straight to your email.

About Spectral Diagnostics

Spectral Medical Inc. focuses on the development and commercialization of products for the treatment of septic shock in the United States, Italy, Ireland, and internationally. The company markets Endotoxin Activity Assay, a rapid in vitro diagnostic test for the detection of components of gram negative bacterial cell wall; and Polymyxin B Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. It also develops and manufactures monoclonal and polyclonal antibodies, recombinant cardiac proteins, and calibrators for use in the research and development, as well as products that are manufactured by other diagnostic companies. The company was formerly known as Spectral Diagnostics (OTCMKTS:EDTXF) and changed its name to Spectral Medical Inc. in December 2014. Spectral Medical Inc. was incorporated in 1991 and is headquartered in Toronto, Canada.

View Spectral Diagnostics Profile
Earnings Tools